ICAP at Columbia University, New York, New York.
US Centers for Disease Control, Division of Global HIV&TB, Atlanta, Georgia.
AIDS. 2023 Jul 15;37(9):1377-1386. doi: 10.1097/QAD.0000000000003581. Epub 2023 Apr 18.
Lesotho does not have reliable data on HIV prevalence in children, relying on estimates generated from program data. The 2016 Lesotho Population-based HIV Impact Assessment (LePHIA) aimed to determine HIV prevalence among children 0-14 years to assess the effectiveness of the prevention of mother-to-child transmission (PMTCT) program and guide future policy.
A nationally representative sample of children under 15 years underwent household-based, two-stage HIV testing from November 2016-May 2017. Children <18 months with a reactive screening test were tested for HIV infection using total nucleic acid (TNA) PCR. Parents (61.1%) or legal guardians (38.9%) provided information on children's clinical history. Children aged 10-14 years also answered a questionnaire on knowledge and behaviors.
HIV prevalence was 2.1% [95% confidence interval (CI): 1.5-2.6]. Prevalence in 10-14 year olds (3.2%; 95% CI: 2.1, 4.2) was significantly greater compared to 0-4 year olds (1.0%; 95% CI: 0.5, 1.6). HIV prevalence in girls and boys was 2.6% (95% CI: 1.8-3.3) and 1.5% (95% CI: 1.0-2.1), respectively. Based on reported status and/or the presence of detectable antiretrovirals, 81.1% (95% CI: 71.7-90.4) of HIV-positive children were aware of their status, 98.2% (95% CI: 90.7-100.0) of those aware were on antiretroviral therapy (ART) and 73.9% (95% CI: 62.1-85.8) of those on ART were virally suppressed.
Despite the roll-out of Option B+ in Lesotho in 2013, pediatric HIV prevalence remains high. Further research is required to understand the greater prevalence among girls, barriers to PMTCT, and how to better achieve viral suppression in children with HIV.
莱索托缺乏儿童艾滋病毒流行率的可靠数据,只能依赖方案数据生成的估计数。2016 年莱索托基于人群的艾滋病毒影响评估(LePHIA)旨在确定 0-14 岁儿童的艾滋病毒流行率,以评估预防母婴传播(PMTCT)方案的效果,并为未来的政策提供指导。
2016 年 11 月至 2017 年 5 月,对 15 岁以下的儿童进行了基于家庭的两阶段艾滋病毒检测,采用全国代表性样本。对筛查试验呈阳性反应且年龄<18 个月的儿童,采用总核酸(TNA)聚合酶链反应(PCR)检测艾滋病毒感染情况。父母(61.1%)或法定监护人(38.9%)提供儿童临床病史信息。年龄在 10-14 岁的儿童还回答了有关知识和行为的问卷。
艾滋病毒流行率为 2.1%[95%置信区间(CI):1.5-2.6]。10-14 岁儿童的流行率(3.2%;95% CI:2.1,4.2)明显高于 0-4 岁儿童(1.0%;95% CI:0.5,1.6)。女孩和男孩的艾滋病毒流行率分别为 2.6%(95% CI:1.8-3.3)和 1.5%(95% CI:1.0-2.1)。根据报告的状态和/或可检测到的抗逆转录病毒药物,81.1%(95% CI:71.7-90.4)的艾滋病毒阳性儿童知晓其状况,98.2%(95% CI:90.7-100.0)的知晓状况的儿童正在接受抗逆转录病毒治疗(ART),73.9%(95% CI:62.1-85.8)的接受 ART 的儿童病毒得到抑制。
尽管莱索托在 2013 年推出了 Option B+,但儿童艾滋病毒流行率仍然很高。需要进一步研究,以了解女孩中较高的流行率、PMTCT 的障碍以及如何更好地实现艾滋病毒儿童的病毒抑制。